UPLOAD Filing
LB PHARMACEUTICALS INC
Date: April 10, 2026 · CIK: 0001691082 · Accession: 0000000000-26-003643
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294900
Letter
Re: LB Pharmaceuticals Inc Registration Statement on Form S-1 Filed April 6, 2026 File No. 333-294900 Dear Heather Turner:
April 10, 2026
Heather Turner Chief Executive Officer LB Pharmaceuticals Inc One Pennsylvania Plaza, Suite 1025 New York, NY 10119
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Brandon Fenn, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 10, 2026 Heather Turner Chief Executive Officer LB Pharmaceuticals Inc One Pennsylvania Plaza, Suite 1025 New York, NY 10119 Re: LB Pharmaceuticals Inc Registration Statement on Form S-1 Filed April 6, 2026 File No. 333-294900 Dear Heather Turner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brandon Fenn, Esq. </TEXT> </DOCUMENT>